Are More Solid Gains On The Horizon For SLDB?

The article provides historical context on gene therapy, noting the concept was proposed in the 1960s and only became a practical reality decades later. It highlights the 2017 approval of Novartis’ Kymriah, the first gene therapy, for children and young adults with a blood cancer.

Analysis

The article provides historical context on gene therapy, noting the concept was proposed in the 1960s and only became a practical reality decades later. It highlights the 2017 approval of Novartis’ Kymriah, the first gene therapy, for children and young adults with a blood cancer.